Steve Warner

机构：Sumitomo Dainippon Pharma (United States)

发表论文 10 篇 · 总被引 158 次 · h-index 3

代表论文

• AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers (2016 · Molecular Cancer Research · 被引 95)
• TP-0903 is active in models of drug-resistant acute myeloid leukemia (2020 · JCI Insight · 被引 34)
• AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages (2023 · Cell Reports · 被引 23)
• Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia (2015 · Cancer Research · 被引 3)
• Abstract 1478: TP-5809, a novel TNK1 inhibitor, suppresses TNK1 dependent signaling and tumor growth in a preclinical model of Hodgkin's lymphoma (2021 · Cancer Research · 被引 1)
• Abstract B29: AXL Inhibitor TP-0903 attenuates TGFβ-Hippo signaling in lung adenocarcinoma cells (2020 · Molecular Cancer Research · 被引 1)